[Skip to Navigation]
Controversies in Neurology
September 2001

Triptans Are All Different

Author Affiliations

From The New England Center for Headache, Stamford, Conn, and the Department of Neurology, Yale University School of Medicine, New Haven, Conn.



Arch Neurol. 2001;58(9):1479-1480. doi:10.1001/archneur.58.9.1479

THERE ARE 4 triptans currently available in the United States, and 3 more are expected to be approved by the Food and Drug Administration. Although they are all 5-HT1B/1D(serotonin1B/1D) agonists, they each have slightly different pharmacokinetic characteristics and clinical strengths and weaknesses, and they can be used in special ways to optimize migraine therapy. Thus, triptans differ significantly clinically, and the astute clinician uses these differences to optimize patient treatment.1,2

Add or change institution